Osimertinib

Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.

The most common side effects include diarrhea, rash, musculoskeletal pain, dry skin, skin inflammation around nails, sore mouth, fatigue and cough.

Osimertinib was approved for medical use in the United States in November 2015, and in the European Union in February 2016.

Emergency Drug has Osicent 80 MG, Osimert 80 MG, Tagrix 40 MG, Tagrix 80 MG in store.

Product categories

Product tags

alectinib Axitinib Baricitinib Brigatinib Caboxen 20mg caboxen 80 mg Cabozanix 80 MG Cabozantinib Crizocent 250 mg 60 TAB Crizotinib Elbonix 25 MG Elopag 25 MG Elopag 50 MG Eltrombopag Ibrutinib Ibrutix 140 MG Ibruxen 140 MG Imanix 400 mg Laronib 25 MG larotrectinib Lenvatinib Nintedanib Obetix 5 MG Olaparib Olaparix 50 MG Olaparix 150 MG Osimertinib Palbociclib Palbonix 125 MG Ponatinib Selcaxen 40 mg Selpercatinib Sofosbuvir sunitinib Sunitix 12.5 MG Sunitix 25 MG Sunitix 50 MG Tagrix 40 MG Tofacinix 5 MG Tofacinix 11 MG Tofacitinib Velpatasvir venetoclax Ventoxen 100 mg 토파시티닙

Showing all 4 results